GlassScriptPhysician profile
Kostas Sideridis
NPI 1003913682
$45,612.63
in general payments reported to CMS, 2019-2025
42 companies · $6,772 in 2025
The $6,772 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,732 · 2020: $2,226 · 2021: $8,294 · 2022: $6,064 · 2023: $9,415 · 2024: $10K · 2025: $6,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Honoraria: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,296.03 |
| Honoraria | $13,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $15,883.56 | 2022-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Redhill Biopharma INC. | $8,157.74 | 2020-2024 | Talicia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,371.59 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $3,299.07 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Qol Medical, LLC | $1,846.66 | 2019-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $1,378.39 | 2020-2023 | |
| Janssen Biotech, INC. | $1,332.29 | 2019-2025 | Tremfya, Stelara, Simponi |
| Ironwood Pharmaceuticals, INC | $1,199.88 | 2019-2024 | Linzess |
| Genzyme Corporation | $1,143.26 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,078.95 | 2019-2025 | Entyvio, Gattex |
| Ardelyx, INC. | $830.29 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $775.92 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $622.10 | 2023-2024 | Wegovy |
| Pfizer INC. | $441.66 | 2019-2025 | |
| Braintree Laboratories, INC. | $425.98 | 2019-2023 | Sutab |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $335.28 | 2023-2025 | Voquezna |
| Celgene Corporation | $309.44 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $300.89 | 2024-2025 | Omvoh, Zepbound |
| Ferring Pharmaceuticals INC. | $290.48 | 2019-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $250.45 | 2019-2023 | Dificid |
| Olympus America INC. | $226.89 | 2023 | Evis Exera Lll Colonovideoscope |
| Vivus LLC | $204.46 | 2020-2025 | Qsymia, Pancreaze |
| Enterra Medical, INC. | $190.96 | 2024-2025 | |
| Dova Pharmaceuticals | $167.89 | 2019 | |
| Aimmune Therapeutics, INC. | $161.45 | 2024-2025 | Zenpep |
| Allergan, INC. | $152.15 | 2019-2020 | |
| Daiichi Sankyo INC. | $138.65 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $137.76 | 2022-2025 | Ocaliva |
| Evoke Pharma, INC. | $133.33 | 2020-2024 | |
| Gilead Sciences, INC. | $129.66 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | Zeposia |
| Janssen Pharmaceuticals, INC | $124.99 | 2024 | Xarelto |
| Pharmacosmos Therapeutics INC. | $114.25 | 2023-2025 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $58.67 | 2025 | Iqirvo |
| Cumberland Pharmaceuticals, INC. | $52.44 | 2024 | Kristalose |
| Alfasigma USA, INC. | $46.46 | 2020-2021 | |
| Romark Laboratories, Lc | $41.97 | 2019 | |
| Concordia Pharmaceuticals INC. | $39.58 | 2019 | |
| Endo Pharmaceuticals INC. | $30.55 | 2019-2020 | |
| Exact Sciences Corporation | $23.55 | 2025 | The Cologuard Plus Collection Kit |
| Valinor Pharma, LLC | $20.09 | 2023 | Movantik |
| Echosens North America, INC. | $18.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kostas Sideridis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.